Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.

In light of recent federal research funding cuts, the Arthritis Foundation and CARRA each contributed an additional $100,000 to support the grant program this year. Meanwhile, demand for research ...

At cloud-based human capital management company Dayforce, adding WellTheory's specialized support to their benefits in ...

Lumos Diagnostics shares today soared by more than 150pc after the company unveiled a US distribution deal worth as much as ...

The diagnosis of several of them can be aided by blood tests and/or imaging. There may not be a cure, but with lifestyle ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025.

Viewing lupus decision aids without interruption leads to better patient-reported outcomes, regardless of whether they are ...

Data suggest that risk of depression, bipolar disorder, and anxiety is nearly twice as high in people with autoimmune ...

A new therapy is showing promise for patients living with the autoimmune condition, rheumatoid arthritis. Dawn Steiner said ...

Senior medical experts have explained why women are more at risk of developing arthritis than men, attributing it to several ...

That research found that prenatal exposure to a number of different maternal autoimmune diseases, including both lupus and ...